Navigation Links
Frontiers news briefs: 27 June
Date:6/28/2013

l division during mitosis. While some tumors maintain a stably aneuploid genome, many cancer cells persistently mis-segregate their chromosomes during mitosis, a phenomenon known as chromosomal instability (CIN). CIN is thought to drive the genomic re-shuffling that enables cells to acquire new phenotypes such as drug resistance and is intimately associated with loss of mitotic fidelity. Emerging data show that CIN and de-regulated cell signaling pathways are closely interrelated suggesting the roles that signaling pathways play in the accuracy of mitosis may be underappreciated. These results imply that the induction of CIN can no longer be thought of as a separate event from the cancer-associated driver mutations found in cell signaling pathways. In the context of tumorigenesis this may turn out to be a double-edged sword that combines de-regulated cell cycle progression with the disruption of mitosis to generate the highly complex genomic rearrangements typical of solid tumors. These results change the way we think about how to intervene therapeutically in cancer patients and provide insights on the molecular targets that may contribute significantly to improve patient prognosis.

Researcher contact:

Prof. Duane A. Compton
Department of Biochemistry
Geisel School of Medicine at Dartmouth, USA
Email: duane.a.compton@dartmouth.edu

URL: http://www.frontiersin.org/Molecular_and_Cellular_Oncology/10.3389/fonc.2013.00164/abstract


'/>"/>

Contact: Gozde Zorlu
gozde.zorlu@frontiersin.org
Frontiers
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Finding new research frontiers in a single cell
2. Frontiers announces launch of new open-access journal, Frontiers in Public Health
3. Frontiers launches new open-access journal in Bioengineering and Biotechnology
4. Frontiers news briefs: May 23
5. Frontiers launches new open-access journal in physics
6. Frontiers news briefs May 30
7. Frontiers news briefs: June 6
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2015)... May 19, 2015 ... the addition of the  "Genetic Testing Market ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic ... analysis of the current and future genetic ... tests, their working principles and types are ...
(Date:5/14/2015)... May 14, 2015  Verificient Technologies, Inc., ... and online remote proctoring, announced a new ... company and creator of the Canvas Learning ... two companies will benefit from the seamless ... As a fully integrated multifactor biometrics ...
(Date:5/11/2015)... 2015 Curemark LLC, a privately held drug ... new Phase III double blind, randomized, placebo-controlled clinical trial ... on all children ages 3-8 with Autism. Previously, Curemark ... double blinded clinical trial for CM-AT in children ages ... digestive enzyme chymotrypsin. This new trial will help determine ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
... CORVALLIS, Ore. Researchers at Oregon State University for the ... overfishing and nitrate pollution can help destroy coral reefs ... bring with it unwanted pathogens, choke off oxygen and disrupt ... big enough to essentially smother corals. They can get out ...
... who take the time to read food labels are ... from a recently released study authored by Steven T. ... of Agriculture,s Department of Agricultural and Resource Economics, in ... Compostela in Spain, the University of Arkansas and the ...
... press release is available in Spanish . ... Development, NEIKER-Tecnalia, and the National Institute of Agricultural Research in ... of ,black dead arm, (BDA) on grapevine leaves are, in ... and BDA are diseases that affect the trunk of ...
Cached Biology News:The 'slippery slope to slime': Overgrown algae causing coral reef declines 2NEIKER and INRA discover that BDA symptoms in grapevine leaves are a sign of esca 2
(Date:5/21/2015)... May 21, 2015  CytRx Corporation (NASDAQ: ... specializing in oncology, today announced positive updated results ... aldoxorubicin for the treatment of unresectable glioblastoma multiforme ... open-label, multisite trial is designed to investigate the ... whose tumors have progressed following prior treatment with ...
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - RepliCel Life ... stage regenerative medicine company focused on the development ... poster presentation at the International Society for Cellular ... chronic Achilles tendinosis currently in a Phase 1/2 ... 29 th from 5:30 PM to 7:00 ...
(Date:5/20/2015)... SAN FRANCISCO, Calif. , May 20, 2015 ... VCYT ) today presented preliminary data demonstrating the ... distinguish idiopathic pulmonary fibrosis (IPF) from other interstitial ... The findings suggest the classifier,s potential to help ... surgery to resolve ambiguity in IPF diagnosis – ...
(Date:5/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ) ... Therapy Market Outlook 2020 " report to their ... and regenerative medicine is expected to have huge marketing ... help in the growth of deregulated organs. Several therapeutic ... unable to form new tissue or sometimes organ transplant ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 2Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 3Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 4Veracyte Presents Preliminary Data Demonstrating Ability of Molecular Classifier to Improve Non-Surgical IPF Diagnosis Using Bronchoscopy Samples 5Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... from the medical community in Europe and the U.S. examined ... disease and sepsis, and in cardiac surgery, during CSL ... in Clinical Fluid Management ." (Logo: ... frank and provocative exchange about the uses and effectiveness of ...
... Inovio Pharmaceuticals, Inc. (NYSE Amex: INO ) ... of Pathology & Laboratory Medicine, University of Pennsylvania, and ... been elected a fellow in the American Association for ... the "father of synthetic DNA vaccines," is being honored ...
... Researchers at Northwestern University have developed a new ... could be a step toward the creation of ... its many promising attributes, graphene is a one-atom ... strength and conductivity. Among graphene,s many possible applications ...
Cached Biology Technology:Medical Experts Who Participated in CSL Behring's Key Issues Dialogue Prefer Albumin for Fluid Management 2Medical Experts Who Participated in CSL Behring's Key Issues Dialogue Prefer Albumin for Fluid Management 3Inovio's Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science 2Inovio's Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science 3Inovio's Scientific Advisory Board Chairman Elected as a Fellow by the American Association for the Advancement of Science 4A step toward better electronics 2
...
... Rabbit polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide ... acids 178-227 of human YBX2. ... is proprietary). ...
... EVO96R and Freedom EVO384R are fast multi-channel ... in three different sizes, with a multi-channel ... deliver significant time saving, with true parallel ... setup of your assays with the Freedom ...
... description: Aminopropylsilane is perhaps ... slide chemistry for microarray ... Slides for Microarrays provide ... substrate for printing PCR ...
Biology Products: